ClinicalTrials.gg
RecruitingNCT07110844Updated Jul 13, 2026

Teclistamab-Daratumumab in AL Amyloidosis

A Phase 2 interventional study of Teclistamab and Daratumumab and Hyaluronidase-fihj in Amyloid Light-chain Amyloidosis, sponsored by Rajshekhar Chakraborty, MD. Recruiting at 3 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Rajshekhar Chakraborty, MD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States — 23 open to participants now, 35 under way, 3 of them phase 3. Immunoglobulin Light-chain Amyloidosis · United States.

Planned enrollment
76th of 114
25 · median 38
Started
2025
with 1 other
Phase 2
49 of 151
5 open now
Primary completion
2031-10
later than 30 of 34 live
Registered
146th of 151
by date

Among the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, this one is the 76th largest by planned enrollment of the 114 interventional ones that give a count, is one of 2 that started in 2025, is one of 49 in phase 2, reaches primary completion later than 30 of the 34 other live ones, and was the 146th registered.

Immunoglobulin Light-chain Amyloidosis

239 studies on the registry are indexed under Immunoglobulin Light-chain Amyloidosis; 63 are open to participants now.

Browse Immunoglobulin Light-chain Amyloidosis studies →

Open to participants now

23 of the 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Immunoglobulin Light-chain Amyloidosis studies recruiting now, 34 (69%) set no upper age limit and 3 (6%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Immunoglobulin Light-chain Amyloidosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.

The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.

Read the detailed description

The purpose of this study is to assess the effectiveness and safety of teclistamab-daratumumab combination in newly diagnosed AL amyloidosis. The study aims to evaluate whether this combination is able to effectively decrease the level of toxic amyloid-producing light chains circulating in the participants' blood, with the overarching goal of avoiding organ damage, improving organ function, and prolonging life.

03

Conditions studied

  • Amyloid Light-chain Amyloidosis

Keywords

  • Untreated AL Amyloidosis
  • untreated light chain amyloidosis
  • light chain amyloidosis
  • AL Amyloidosis
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years and able to sign Form (ICF). If the individual being considered for participation in this study is unable to provide informed consent due to medical, cognitive, or other conditions, a legally authorized representative (LAR) may consent on their behalf.
  2. Ability to comply with the study protocol, in the investigator's judgment.
  3. Confirmed histopathological diagnosis of systemic AL amyloidosis by mass spectrometry or immunohistochemistry (IHC) or Immunofluorescence (IF) on a tissue that is positive for Congo Red.
  4. Patient must not have received any prior plasma cell clone-directed therapy.
  5. Measurable hematologic disease, defined as one of the following:

    1. Difference between involved and uninvolved serum free light chain (dFLC) ≥50 mg/L and/or 5 mg/dL
    2. Serum M-protein ≥0.5 g/dL on protein electrophoresis
  6. (ECOG) performance status of 0, 1, or 2.
  7. One or more organs involved by AL amyloidosis as per consensus guidelines
  8. Pre-treatment clinical laboratory values meeting the following criteria during the screening phase:

    1. ≥0.75 × 10\^9/L
    2. level ≥8.0 g/dL; red blood cell transfusion allowed until 7 days before C1D0.
    3. count ≥50 × 10\^9/L; Platelet transfusions are acceptable without restriction during the Screening period
    4. level (ALT) ≤2.5 times the (ULN)
    5. Aspartate aminotransferase (AST) ≤2.5 times the ULN
    6. Total level ≤1.5 × ULN except for subjects with Gilbert syndrome, in which case direct bilirubin ≤2 × ULN
    7. Estimated (eGFR) ≥20 mL/min/1.73 m\^2, measured by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  9. For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use and agreement to refrain from donating eggs.

For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  1. Prior therapy for AL amyloidosis or multiple myeloma with the exception of 160 mg dexamethasone (or equivalent ) maximum exposure prior to C1D0.
  2. Patients meeting criteria for symptomatic multiple myeloma by any one of the following: (a) Lytic lesions on imaging (Skeletal survey, whole body CT or MRI, or PET/CT) (b) Plasmacytoma, (c) Hypercalcemia without any alternate etiology, (d) Bone marrow plasma cell infiltrate of greater than 60%.

    Patients with involved/uninvolved serum FLC ratio>100 as the sole myeloma-defining event will be allowed.

  3. Evidence of significant cardiovascular conditions as specified below:

    1. NT-Pro BNP > 8500 pg/mL, and/or
    2. Class IIIb or IV functional class
  4. History of other that could affect compliance with the protocol or interpretation of results.

    Patients with a history of curatively treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, breast cancer, or Hodgkin's Lymphoma are generally eligible. Patients with a malignancy that has been treated, but not with curative intent, will be excluded, unless the malignancy has been in remission without treatment for ≥ 2 years prior to enrollment.

  5. Evidence of other uncontrolled condition(s) including, but not limited to, uncontrolled systemic infection (viral, bacterial, or fungal).
  6. Patients on renal replacement therapy
  7. Patients with who are not on HAART or those with active hepatitis A, B, or C infection.
  8. Planned stem cell transplant during the first 6 cycles of protocol therapy are excluded. Stem cell collection during the first 6 cycles of protocol therapy is permitted, as per investigators' discretion.
  9. Known to any of the agents
  10. Patients who are receiving any other agent concurrently.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Teclistamab-Daratumumab

    All participants in this study will receive teclistamab and daratumumab.

    Drug: Teclistamab · Drug: Daratumumab and Hyaluronidase-fihj

Interventions

  • Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.

    Also known as: TECVAYLI, teclistamab-cqyv

  • DrugDaratumumab and Hyaluronidase-fihj

    Drug page: Daratumumab and Hyaluronidase-fihjStudies of Daratumumab and Hyaluronidase-fihjDaratumumab and Hyaluronidase-fihj pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.

    Also known as: DARZALEX FASPRO, Daratumumab

06

What researchers measure

Primary outcomes

  1. Hematologic Complete Response (Heme-CR) rate

    Heme-CR will be defined as: involved free light-chain level less than the upper limit of the normal range with negative serum and urine immunofixation; normalization of the uninvolved free light-chain level or free light-chain ratio will not be required to determine a complete response.

    Time frame: 6 months from treatment initiation

Secondary outcomes

  1. Minimal Residual Disease (MRD) negativity rate by Free Light Chain Mass Spectrometry (FLC-MS) in serum

    Secondary outcome is to assess the rate of minimal residual disease (MRD)-negativity and sustained MRD-negativity with Teclistamab-Daratumumab

    Time frame: 1 month, 3 months, 6 months, and 18 months

  2. MRD-negativity rate by multiparameter flow cytometry (MFC) in bone marrow

    The MRD-negativity rate by 6 and 18 months will be reported descriptively.

    Time frame: 6 months and 18 months

  3. Time to heme-CR

    Time to heme-CR will be calculated from the day of treatment initiation (C1D0), and will be reported as median (range).

    Time frame: Day 1 of each cycle, and every 6 weeks after treatment cessation (up to 1 year)

  4. Major organ deterioration-progression-free survival (MOD-PFS) rate

    MOD-PFS will be calculated as a time-to-event endpoint using Kaplan-Meier method.

    Time frame: From Cycle 2 to Cycle 6 Day 1 (Each cycle is 28 days), End of treatment visit (up to 6 months from treatment initiation), and up to 18 months from treatment initiation

  5. Overall survival rate

    Overall survival frequency from initiation of study drug, including cause of death for patients who die on study

    Time frame: Through study completion, up to 18 months from treatment initiation

  6. Frequency of Cytokine Release Syndrome (CRS)

    Frequency of CRS (all-grade and grade ≥3) events

    Time frame: Throughout Cycle 1 (each cycle is 28 days), Day 0, Day 1, Day 3, Day 8, Day 15, Day 22; Throughout Cycle 2 and Cycle 6 on Day 1 and Day 15; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months)

  7. Rate of infections

    Frequency rate of infections (all-grade and grade ≥3) will be reported descriptively.

    Time frame: Throughout Cycle 1 (each cycle is 28 days), Day 0, Day 1, Day 3, Day 8, Day 15, Day 22; Throughout Cycle 2 and Cycle 6 on Day 1 and Day 15; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months)

  8. Number of participants with a heart response after treatment

    Heart response is defined as N-terminal pro Brain Natriuretic Peptide (NT-ProBNP) response (\>30% and \>300 ng/l decrease in subjects with baseline NT-proBNP\>650 ng/l) or New York Heart Association (NYHA) class response (\>2 class decrease in subjects with baseline NYHA class 3 or 4)

    Time frame: 6 months and 18 months

  9. Number of No Responses in the heart after treatment

    No response in the heart is defined as ≤30% reduction in NT-proBNP from baseline

    Time frame: 6 months and 18 months

  10. Number of Partial Responses (PR) in participants who experienced a heart response after treatment

    Partial Response in the heart is defined as 31-60% reduction in NT-proBNP from baseline.

    Time frame: 6 months and 18 months

  11. Number of Very Good Partial Responses (VGPR) in participants who experienced a heart response after treatment

    VGPR in the heart is defined as \>60% reduction in NT-proBNP from baseline to a nadir of \>350 ng/L

    Time frame: 6 months and 18 months

  12. Number of Complete Response (CR) in participants who experienced a heart response after treatment

    Complete Response in the heart is defined as Nadir NT-proBNP≤350 ng/L

    Time frame: 6 months and 18 months

  13. Number of participants with heart progression after treatment

    Heart progression is defined as NT-proBNP progression (\>30% and \>300 ng/l increase) or cardiac troponin progression (\>33% increase) or ejection fraction progression (\>10% decrease). Subjects with progressive worsening renal function cannot be scored for NT-proBNP progression.

    Time frame: 6 months and 18 months

  14. Number of participants with a kidney response after treatment

    Kidney response is defined as 50% decrease (at least 0.5 g/day) of 24-h urine protein (urine protein must be \>0.5g/day pretreatment). Creatinine and creatinine clearance must not worsen by 25% over baseline.

    Time frame: 6 months and 18 months

  15. Number of No Responses in the kidneys after treatment

    No response in the kidneys is defined as ≤30% reduction in proteinuria from baseline

    Time frame: 6 months and 18 months

  16. Number of Partial Responses (PR) in participants who experienced a kidney response after treatment

    Partial Response in the kidneys is defined as 31-60% reduction in proteinuria from baseline

    Time frame: 6 months and 18 months

  17. Number of Very Good Partial Responses (VGPR) in participants who experienced a kidney response after treatment

    VGPR in the kidneys is defined as \>60% reduction in proteinuria from baseline level to a nadir level \>200 mg/24 hours

    Time frame: 6 months and 18 months

  18. Number of Complete Response (CR) in participants who experienced a kidney response after treatment

    Complete Response in the kidneys is defined as Nadir proteinuria ≤200 mg/24 hours

    Time frame: 6 months and 18 months

  19. Number of participants with kidney progression after treatment

    Kidney progression is defined as 50% increase (at least 1 g/day) of 24-h urine protein to \>1 g/day or 25% worsening of serum creatinine or creatinine clearance.

    Time frame: 6 months and 18 months

  20. Number of participants with liver response after treatment

    Liver response is defined as 50% decrease in abnormal alkaline phosphatase value.

    Time frame: 6 months and 18 months

  21. Number of No Responses in the liver after treatment

    No response in the liver is defined as ≤30% reduction in alkaline phosphatase (ALP) from baseline.

    Time frame: 6 months and 18 months

  22. Number of Partial Responses (PR) in participants who experienced liver response after treatment

    Partial Response in the liver is defined as 31-60% reduction in ALP from baseline.

    Time frame: 6 months and 18 months

  23. Number of Very Good Partial Responses (VGPR) in participants who experienced liver response after treatment

    VGPR in the liver is defined as \>60% reduction in ALP from baseline to a nadir \>2x lower limit of normal (LLN)

    Time frame: 6 months and 18 months

  24. Number of Complete Response (CR) in participants who experienced liver response after treatment

    Complete Response in the liver is defined as Nadir ALP ≤2X LLN

    Time frame: 6 months and 18 months

  25. Number of participants with liver progression after treatment

    Liver progression is defined as 50% increase of ALP from nadir value

    Time frame: 6 months and 18 months

Other outcomes

  1. Hematologic event-free survival (Heme-EFS)

    Heme-EFS will be calculated as a time-to-event endpoint using Kaplan-Meier method.

    Time frame: Throughout Cycle 2 and Cycle 6 (each cycle is 28 days) on Day 1; End of treatment visit (up to 6 months from treatment initiation), Post treatment follow-up (up to 18 months from treatment initiation)

  2. CD4 cell count

    CD4 cells will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

  3. CD8 cell count

    CD8 cells will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

  4. CD19 cell count

    CD19 cells will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

  5. IgG level

    IgG titers will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

  6. IgA level

    IgA titers will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

  7. IgM level

    IgM titers will be measured in participants before and after treatment.

    Time frame: Baseline until 18 months from treatment initiation

07

Study locations

2 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2031, 71 months after the start.

Of 31 phase 2 interventional studies under Immunoglobulin Light-chain Amyloidosis, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 71 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 8, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Oct 2031
CompletionEst.
Oct 2033
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07110844
Lead sponsor
Rajshekhar Chakraborty, MD
Responsible party
Rajshekhar Chakraborty, MD (Assistant Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Aug 8, 2025
Start date
Nov 7, 2025
Primary completion
Oct 2031 (estimated)
Completion
Oct 2033 (estimated)
Last update
Jul 13, 2026

Study contacts

Central Nurse Navigator, RN
Contact
cancerclinicaltrials@cumc.columbia.edu
(212) 342 5162
Rajshekhar Chakraborty, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Teclistamab · Daratumumab and Hyaluronidase-fihj

Start the discussion